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Abstract
Background: The enzyme indoleamine 2,3-dioxygenase (IDO) contributes to immune tolerance in a variety of settings. In
cancer IDO is expressed within the tumor itself as well as in antigen-presenting cells in tumor-draining lymph nodes, where
it endorses the establishment of peripheral immune tolerance to tumor antigens. Recently, we described cytotoxic CD8
+ T-
cell reactivity towards IDO-derived peptides.
Methods and Findings: In the present study, we show that CD4
+ helper T cells additionally spontaneously recognize IDO.
Hence, we scrutinized the vicinity of the previously described HLA-A*0201-restricted IDO-epitope for CD4
+ T-cell epitopes.
We demonstrated the presence of naturally occurring IDO-specific CD4
+ T cells in cancer patients and to a lesser extent in
healthy donors by cytokine release ELISPOT. IDO-reactive CD4
+ T cells released IFN-c, TNF-a, as well as IL-17. We confirm
HLA class II-restriction by the addition of HLA class II specific blocking antibodies. In addition, we detected a trend between
class I- and class II-restricted IDO responses and detected an association between IDO-specific CD4
+ T cells and CD8
+ CMV-
responses. Finally, we could detect IL-10 releasing IDO-reactive CD4
+ T cells.
Conclusion: IDO is spontaneously recognized by HLA class II-restricted, CD4
+ T cells in cancer patients and in healthy
individuals. IDO-specific T cells may participate in immune-regulatory networks where the activation of pro-inflammatory
IDO-specific CD4
+ responses may well overcome or delay the immune suppressive actions of the IDO-protein, which are
otherwise a consequence of the early expression of IDO in maturing antigen presenting cells. In contrast, IDO-specific
regulatory T cells may enhance IDO-mediated immune suppression.
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Introduction
Indoleamine 2,3-dioxygenase (IDO) has attracted much inter-
est, since it is involved in the generation of immune tolerance in a
variety of physiological and pathological settings. The immuno-
logical effects of IDO are mainly limited to acquire peripheral
tolerance or unresponsiveness to novel antigens. Thus, it does not
seem to be required for constitutive tolerance to self antigens.
Hence, systemic inactivation at the organism level, either
pharmacologically or genetically, does not appear to cause severe
autoimmunity [1]. IDO mediated degradation of the essential
amino acid tryptophan to kynurenine and other downstream
metabolites suppresses effector T-cell function [2,3]. In addition,
this seem to facilitate the conversion of naı ¨ve T lymphocytes into
Tregs [4,5]. IDO can be expressed by a variety of cell types,
including dendritic cells (DC), tumor cells and stoma cells. In
cancer, IDO is involved in the induction of tolerance towards
tumor antigens and to facilitate immune escape [6,7].
Consistent with a role for IDO in mediating tolerance to
tumors, preclinical studies have shown the promise of IDO
inhibitors in the targeting of several cancers [8–14]. We have
recently described the presence of CD8
+, cytotoxic IDO-reactive
T cells in peripheral blood of both cancer patients and healthy
donors. We demonstrated that IDO-specific CD8
+ T cells were
able to recognize and kill tumor cells including directly isolated
AML blasts as well as IDO-expressing DC, i.e. one of the major
immune suppressive cell populations [15]. Furthermore, we
showed that the presence of such IDO-specific CD8
+ T cells
boosted T-cell immunity against viral or tumor-associated
antigens by eliminating IDO
+ suppressive cells [16]. Hence,
IDO-specific effector T cells may play a vital role for the
mounting or maintaining of an effective adaptive immune
response.
In the present study, we show that IDO is in addition the target
for CD4
+ T-helper cells.
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Donors
Peripheral Blood Mononuclear Cells (PBMC) were collected
from healthy individuals and cancer patients (renal cell carcinoma,
melanoma, and breast cancer). The PBMC from cancer patients
were obtained prior to entering into clinical trials, which were
concurrently approved by the Danish Medicines Agency and
registered at www.clinicaltrials.gov. Identifier (renal cell carcinoma
trial: NCT00197860, melanoma trials: NCT00978913 &
NCT00197912, breast cancer trial: NCT00197925). Written
informed consent from the donors was obtained before study
entry. All patients had histological verified metastatic disease (stage
IV TNM classification) at inclusion. Blood samples from cancer
patients were drawn a minimum of four weeks after termination of
any kind of anti-cancer therapy. The majority of renal cell
carcinoma patients had previously been treated with IL-2 and
IFN-a, most melanoma patients had received high dose IL-2 and
IFN-a, while all breast cancer patients were pre-treated with
several kinds of chemotherapy, (e.g. epirubicin, docetaxel,
cabecitabine), trastuzumab, and/or endocrine therapy. PBMC
were isolated using lymphoprep separation, HLA-typed (Depart-
ment of Clinical Immunology, University Hospital, Copenhagen,
Denmark) and frozen in FCS with 10% DMSO. The protocols
were approved by the Scientific Ethics Committee for The Capital
Region of Denmark and conducted in accordance with the
provisions of the Declaration of Helsinki.
Peptides
Three synthetic peptides were synthesized (TAG Copenhagen,
Copenhagen, Denmark): DTLLKALLEIASCLE (IDO194-208)
entitled IDO194, LLEIASCLEKALQVF (IDO200-214) entitled
IDO200 as well as DTLLKALLEIASCLEKALQVF (IDO194-
214) entitled IDOlong. Although the IDO1 and IDO2 proteins
share 43% identity at the amino acid level, only 5 out of 21 amino
acids from the IDOlong peptide sequence can be found identical
in the IDO2 protein sequence. Additional peptides included:
HLA-A2-restricted ALLEIASCL (IDO199-207) entitled IDO5;
the HLA-A2 -restricted epitope CMV pp65495–503
(NLVPMVATV), the HLA-A11-rstricted epitope CMV pp6516–
24 (GPISGHVLK), the HLA-A1 and HLA-A24 restricted epitope
CMV pp65341–350 (QYDPVAALFF) or the HLA-A1 restricted
epitope CMV pp65363–373 (YSEHPTFTSQY). Finally a nonsense
peptide (GARVERVDFGNFVFNISVLW) was used as irrelevant
control.
ELISPOT assay
The ELISPOT assay was used to quantify peptide-specific IFN-
c, TNF-a or IL-17 releasing effector cells as described [17]. PBMC
were stimulated once in vitro with peptide or with DC pulsed with
peptide prior to analysis as described [18] to extend the sensitivity
of the assay. After seven days in culture with 25 mg/ml peptide and
20 U/ml IL-2 (PeproTech, London, UK), cells were counted and
analyzed in ELISPOT. Briefly, nitrocellulose bottomed 96-well
plates (MultiScreen MAIP N45; Millipore) were coated overnight
with IFN-c, TNF-aor IL-17 capture mAb (Mabtech, Nacka
Strand, Sweden). The wells were washed, blocked by X-vivo
medium. PBMC or isolated CD4
+ cells with or without DC were
added in duplicates at different cell concentrations, with or without
5 mg/ml peptide. The plates were incubated overnight. The
following day, medium was discarded and the wells were washed
prior to addition of appropriate biotinylated secondary mAb
(Mabtech). The plates were incubated at room temperature (RT)
for 2 hours, washed, and Avidin-enzyme conjugate (AP-Avidin;
Calbiochem/Invitrogen Life Technologies) was added to each
well. Plates were incubated at RT for 1 hour and the enzyme
substrate NBT/BCIP (Invitrogen Life Technologies) was added to
each well and incubated at RT for 5–10 min. Upon the
emergence of dark purple spots, the reaction was terminated by
washing with tap water. The spots were counted using the
ImmunoSpot Series 2.0 Analyzer (CTL Analyzers). CD4
+ cells
were isolated either using CD4 MicroBeads or EasySep human
CD4
+ cell enrichment kit according to manufacturers protocol by
Miltenyi Biotech or Stem Cell Technology, respectively. The
purity was subsequently analyzed by FACS on a FACS Canto
using CD3-FITC, CD4-PE and CD8-APC conjugated antibodies
(BD Biosciences). For class II-restriction assays 2 mg/ml HLA class
II antibody (Monoclonal Antibody (MBS140186), MyBioSource,
San Diego, US) were added to ELISPOT wells for K hour before
the addition of IDOlong peptide.
For ex vivo ELISPOT analysis, CD4 T-cells were purified and
directly plated on IFN-c capture mAb coated plate with or without
IDOlong-pulsed autologous DC. To correlate IDOlong responses
with HLA class I-restricted IDO5 or CMV epitopes, in vitro or
ex vivo IFN-c ELISPOT was performed as described above. For
the induction of IDO specific T-cells by Cytosine-phosphate-
Guanine (CpG) ODN (Type B CpG oligodeeoxynucleotide
specific for human TLR9; InvivoGen), PBMC were stimulated
with 40 U/ml IL-2 with and without 1 ug/ml of CpG for two
weeks before analysis. For the examination of patient character-
istics and of the nature of cytokines concomitantly secreted by each
patient, IDO responders were defined as average number of
antigen specific cells 6K standard deviation .25 per
5610
5 PBMC.
Intracellular Staining for IFN-c, TNF-a, Il-17
For detection of cell subpopulations producing cytokines,
PBMC that were cultured for seven days in the presence of
peptide as described for ELISPOT, were stimulated with IDOlong
(5 mg/ml) for 5 hours at 37uC with 5% CO2 in air. Positive control
wells were set-up with the addition of SEB (5 mg/ml). GolgiPlug
(BD) was added at a dilution of 1:200 after the first hour of
incubation. After 4 additional hours cells were washed twice with
PBS, stained fluorochrome conjugated antibodies for surface
markers (CD3-Amcyan, CD4-PerCP and CD8-Pacific Blue, all
from BD). Cells were washed one additional time and thereafter
fixed and permeabilized with Fixation/Permeabilization and
Permeabilization Buffer (eBioscience), according to manufacturer’s
instructions. Cells were subsequently stained with fluorochrome-
conjugated antibodies for intracellular cytokines. The following
combinations were used: IFNc-PeCy7 (BD), TNFaAPC
(eBioscience) and IL-17a-FITC (eBioscience). Relevant isotype
controls were used to enable correct compensation and confirm
antibody specificity. At least 10
5 CD4
+ T cells were acquired.
Stained cells were analyzed using a BD FACSCanto II flow
cytometer. Analysis was performed with BD FacsDiva Software.
For the generation of IDOlong specific bulk cultures PBMC
were stimulated twice with autologous DC matured with IDOlong
peptide and 120 U/ml IL-2. Seven days after the second
stimulation, PBMC were stimulated with autologous DC matured
either with an irrelevant 20 amino acid long nonsense peptide,
IDOlong peptide, lysate from the IDO
+ colon cancer cell line
SW480 (available at the American Type Culture Collection
(ATCC)), or lysate from the IFN-c pre-treated (100 U/ml for
three days) melanoma cell line MM404.111 for 5 hours. After
stimulation, intracellular cytokine staining was performed as
described above in this section. Expression of IDO by SW480
CD4
+ T-Cell Responses against IDO
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(data not shown).
Results
Selection of a 21 Amino Acid Long Peptide from IDO
Previously, we characterized an HLA-A2-restricted, IDO-
derived CD8
+ T cell epitope from IDO199-207 (ALLEIASCL).
This peptide is included in an ongoing first-in-man phase I
vaccination trial at Center for Cancer Immune Therapy, Herlev
Hospital, Denmark in patients with non small cell lung cancer
(NSCLC) (www.clinicaltrials.gov; NCT01219348). In the present
study, we sat out to examine if IDO in addition serve as target for
CD4
+ immune responses. Instead of examining spontaneous
immune response against overlapping peptides covering all of the
403 amino acids in the IDO sequence, which would require large
quantities of human PBMC, we focused on the region IDO199-
207, which have previously been described to be immunogenic. In
this respect, it has been described that T-cell epitopes often cluster
together at specific immunogenic regions. Thus, we examined the
region containing the HLA-A2-restricted epitope for potential
class II epitopes using the predictive algorithm developed by
Rammensee et al. available at www.syfpeithi.de.’’ [19]. The
algorithm selected a 15 mer peptide DTLLKALLEIASCLE
(IDO194-208) to be a high affinity HLA-DRB1*0101-restricted
epitope and a 15 mer peptide LLEIASCLEKALQVF (IDO200-
214) to be a high affinity HLA-DRB1*0301-restricted epitope.
Consequently, we synthesized a 21 amino acid peptide entitled
IDOlong containing both peptides (DTLLKALLEIASCLE-
KALQVF (IDO194-214)). The predictive algorithm additionally
proposed that this sequence contains HLA-DRB1*0401, HLA-
DRB1*0701 as well as HLA-DRB1*1501 15 mer epitopes.
Spontaneous Cytokine Release in Response to IDOlong
Peptide
Using the IFN-c, TNF-a, IL-17 ELISPOT secretion assays, we
examined peripheral blood T cells from cancer patients and
healthy individuals for the presence of specific T-cell responses
against IDOlong. Thus, PBMC from late stage cancer patients
(breast cancer, melanoma and renal cell carcinoma) were
stimulated once with the IDOlong peptide in vitro before
examination by ELISPOT. Frequent ELISPOT responses against
IDOlong were detected in IFN-c, TNF-a as well as IL-17 assays
(Figure 1, 2 and 3). Furthermore, we found that circulating IDO-
specific, CD4
+ T cells were present in healthy donors. We recently
described that healthy individuals likewise harbor CD8
+ specific
T-cell responses [16]. We further assayed if we could detect
responses against IDOlong directly in ex vivo ELISPOT in PBMC
from eight patients. The frequency of IDO-reactive T cells were
markedly increased by in vitro stimulation, although IDO-reactive
T cells were readily detectable ex vivo in one breast cancer patient
(150 IDOlong reactive cells/6610
5 PBMC; data not shown).
Figure 1D illustrates that we could detect immune response against
at least one cytokine in almost 80% of the examined donors. In
26% we detected a response against one of either IFN-c, TNF-a or
IL-17, in 35% against two cytokines and in 17% of the donors we
detected a response against all three cytokines.
Class II-restriction of IDOlong Responses
Next, we confirmed that the CD4 T-cell responses against
IDOlong were indeed HLA class II-restricted responses. Hence,
we examined the effect of the addition of anti-HLA class II
blocking antibody to ELISPOT assays with PMBC from six
IDOlong responding donors. As shown in figure 2 the IDOlong-
responses were robustly inhibited by anti-HLA class II blocking
antibodies in PMBC from all donors.
CD4
+ T Cell Responses Against IDOlong
We further confirmed that the ELISPOT responses indeed were
CD4
+ T-cell responses. Hence, CD4
+ cells were isolated from
three responding donors before examination by ELISPOT against
DC without or pre-pulsed with IDOlong. The purity of the CD4
isolations was above 97% (data not shown). These measures
confirmed that CD4
+ T cells were indeed responsible for the
response against the IDOlong peptide (Figure 3A). Next, we
examined if IDOlong responses were detectable directly ex vivo
without the need of a prior in vitro peptide stimulation step. Thus,
CD4
+ cells were isolated from PBMC from three different donors
and directly added to ELISPOT assays with autologous DC with
and without IDOlong. From figure 3 it can be seen that it was
indeed possible to detect CD4 specific T-cell reactivity against
IDO in the three donors. The IFN-c release could be blocked by
the addition of HLA-class II antibody (Figure 3B).
Intracellular Cytokine Stainings
The T-cell mediated recognition of IDOlong was additionally
analyzed by intracellular cytokine stainings (ICS) (IFN-c, TNF-a,
IL-17) in six cancer patients. These analyses appeared less sensitive
than the ELISPOT. Thus, we could not detect IL-17 release by
ICS in any of the patients. However, in two melanoma patients we
could detect a CD4
+ specific release of TNF-a and to a lesser
extend IFN-c in response to IDOlong (figure 4A). Having
identified donors hosting responses against the IDOlong peptide,
we used PBMC from a responding melanoma patient to generate
a bulk culture against this peptide in vitro. Subsequently, we in vitro
stimulated PBMC with IDOlong-pulsed autologous DC. After
three in vitro re-stimulations, the peptide specificity was tested using
IFN-c, TNF-a intracellular staining (figure 4B). This assay
revealed that around 3% of the culture released IFN-c in response
to autologous DC pulsed with IDOlong, around 4.4% released
TNF-a and almost 2% both cytokines. As a control we stimulated
the bulk culture with autologous DC pulsed with a 20 amino acid
long irrelevant, nonsense peptide (GARVERVDFGNFVF-
NISVLW) (figure 4B). Next, we examined the recognition of
IDO
+ tumor lysates by the IDOlong reactive bulk culture. Hence,
we examined the bulk cultures reactivity against autologous DC
pulsed with either lysate from the IDO
+ colon cancer cell line
SW480 or lysate from the melanoma cell line MM404.111.
MM404.111 did not express IDO and was consequently pre-
treated with IFN-c. From figure 4B it can be seen that the bulk
culture reacted towards both IDO
+ tumor lysates.
Correlation Between IDOlong Responses and CD8 T-cell
Responses Against IDO as well as CMV
The IDOlong peptide contains the region IDO199-207, which
cover the HLA-A2-restricted, IDO-derived CD8
+ T cell epitope
named IDO5. Thus, first we examined the correlation between
IDOlong responses and the class I tissue type HLA-A2 (figure 5A
and 5B). Indeed, more IDOlong responders were identified among
HLA-A2 positive donors. A Mann-Whitney test demonstrated a
significant difference for IFN-c responders (P=0.0003 for IFN;
P=0.2 for TNF-a). Next, we examined the CD8 T-cell response
against IDO5 in the PBMC from the donors included in this study
(figure 5C) by ELISPOT assay. Indications of a trend between
CD4 and CD8 responses against the two IDO peptides was found
although not significant (P=0.21; Mann-Whitney test). Previously,
we have described that CMV-specific CD8
+ T-cell responses were
CD4
+ T-Cell Responses against IDO
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34568Figure 1. T-cell responses against IDOlong. (A), T-cell responses against IDOlong (DTLLKALLEIASCLEKALQVF (IDO194-214)) as measured by IFN-
cELISPOT: Example of an ELISPOT response against IDOlong in PBMC from a renal cell carcinoma patient (Top). The average number of IDOlong-
specific spots (after subtraction of spots without added peptide) was calculated per 5610
5 PBMC for each patient. PBMC from ten healthy individuals
(HD), twenty three melanoma patients (MM), fifteen renal cell carcinoma patients (RCC) as well as nine breast cancer patients (BC) were analyzed.
CD4
+ T-Cell Responses against IDO
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notably, we found IDO-specific CD8
+ T-cell responses in three
healthy donors, which in addition all had strong CMV-specific
CD8
+ T-cells responses. Hence, we examined if there was any
correlation between IDOlong responses and T-cell responses
against the most immunogenic HLA class I-restricted CMV-
epitopes, i.e. the HLA-A2-restricted epitope CMV pp65495–503
(NLVPMVATV), the HLA-A11-restricted epitope CMV pp6516–
24 (GPISGHVLK), the HLA-A1- and HLA-A24-restricted epitope
CMV pp65341–350 (QYDPVAALFF) as well as the HLA-A1-
restricted epitope CMV pp65363–373 (YSEHPTFTSQY)
(Figure 5D). Hence, we analysed PBMC from the donors included
in this study against reactivity against the CMV-derived epitopes
in direct ELISPOT assays without any prior stimulation. A Mann-
Whitney test illustrated that there was significant difference in T
cell reactivity towards CMV epitopes between IDOlong respond-
ers and non-responders (P=0.04).
Patient Characteristics
From 20 patients with disseminated malignant melanoma we
had access to clinical patient records during treatment. Within this
group 12 patients had a measurable CD4
+ T-cell IFN-y ELISPOT
response towards IDOlong; whereas 8 patients did not respond.
Clinical data are summarized in Table 1. All patients had
histological verified stage IV malignant melanoma (UICC TNM
Classification) and had measurable disease according to RECIST
criteria version 1,0 [20]. In Denmark systemic treatment with high
dose Interleukin 2/Interferon (IL-2/IFN – Keilholz decrescendo
regime [21]) is 1
st line treatment for patients with metastatic
malignant melanoma. Other available systemic treatments consist
of anti-CTLA-4 antibody (ipilimumab), BRAF inhibitor (vemur-
afenib), temozolamide and experimental treatments i.e. DC
vaccines, CD137 and T-cell therapy. In average, the IDOlong
responders had received less overall systemic treatments (2.5 vs.
2.9 regimes) at the time of analysis (Figure 6A). Furthermore, in
average patients responding to IDOlong had received more IL-2/
IFN treatment than the non-responding patients (3.2 vs. 2.3
cycles), thus indicating a positive correlation between IL-2/IFN
treatment and anti-IDO response (Figure 6B). Furthermore,
interestingly a trend was found in the IDOlong responding
patients towards an extended period of stable disease after IL-2/
IFN therapy (SD 3,8 vs. 2,1 months) compared to the non-
responding patients, however this did not reach statistical
significance (p=0,28) (Figure 6C). Furthermore, the responders
did prove to have a prolonged survival (19.3 vs. 17.3 months) from
diagnosis of disseminated malignant melanoma until death,
although again not statistically significant (p=0.87) (Figure 6D).
IDOlong Contains Various T Cell Epitopes
The predictive algorithm [19] suggested that two high affinity
15 mer class II epitopes were contained in IDOlong namely
DTLLKALLEIASCLE (IDO194-208) and LLEIASCLE-
KALQVF (IDO200-214). We analysed 7 cancer patients (1 breast
cancer patient and 6 melanoma patients) for responses against
these 15 mer peptide. In two patients a strong response against
DTLLKALLEIASCLE (IDO194-208) were detected whereas
weak responses against LLEIASCLEKALQVF (IDO200-214)
were detected in most patients (Figure 7A). Interestingly, in most
patients IDOlong induced stronger responses than the two 15 mer
peptides, which could suggest that the predictive algorithm may
underestimate the complex regulation of IDO [22].
CpG Stimulate IDO-specific T Cells
Triggering of functional IDO requires ligation of B7-1/B7-2
molecules on DC by CTLA4/CD28 expressed on T cells [23].
TLR9 ligation activates DC to up regulate surface expression of
B7 ligands and thereby increase expression of IDO [24]. To
determine whether this TLR9 ligand-induced up regulation of
IDO expression additionally activates CD4 IDO-specific T cells,
PBMC from three cancer patients were treated with the TLR9
ligand CpG ODN in the presence of IL-2 for 14 days and,
subsequently, examined for IDO-specific T cells. TLR9 signaling
with CpG ODN induced a measurable number of IDO-specific
T cells in two of the patients (Figure 7B).
Spontaneous IL-4 or IL-10 Release in Response to
IDOlong Peptide
We examined PMBC from 12 individuals for release of IL-4 in
response to IDOlong stimulation. However, we could not detect
IL-4 response in any of the examined samples (data not shown).
Next, we examined the release of IL-10 in response to IDOlong
(Figure 8). We could detect IL-10 release especially in some
melanoma patients as well as healthy donors (Figure 8). Notably,
in two healthy donors we observed a decrease in IL-10 release
compared to background levels.
Discussion
IDO is an immunoregulatory enzyme that is implicated in
immunity under normal and pathological settings [6]. It was
recently shown that IDO provides a potential mechanism for the
development of DC-mediated T-cell tolerance [25]. IDO
+ DC
inhibit T-cell proliferation due to tryptophan depletion and
accumulation of toxic tryptophan metabolites [6]. We have
recently described that peptides comprised in the IDO protein
sequence are spontaneously recognized by CD8
+, cytotoxic T cells
in cancer patients [15] and healthy individuals [16]. IDO reactive
CD8
+ T cells were able to recognize and kill IDO expressing cells,
e.g. tumor cells or regulatory DC. Importantly, the presence of
such IDO-specific CD8
+ T cells boosted T-cell immunity against
viral or tumor-associated antigens by eliminating IDO
+ suppres-
sive cells thereby directly targeting the IDO-dependent counter-
regulatory pathway [16]. In the present story, we describe that a
long peptide spanning the region around the previously described
PBMC were stimulated once with peptide before being plated at 5610
5 cells per well in duplicates either without or with the IDOlong peptide
(bottom). (B), T-cell responses against IDOlong as measured by TNF-a ELISPOT: Example of an ELISPOT response against IDOlong in PBMC from a
melanoma patient (Top). The average number of IDOlong-specific spots (after subtraction of spots without added peptide) was calculated per 5610
5
PBMC for each patient. PBMC from eleven healthy individuals (HD), eighteen melanoma patients (MM), fourteen renal cell carcinoma patients (RCC) as
well as nine breast cancer patients (BC) were analyzed. PBMC were stimulated once with peptide before being plated at 5610
5 cells per well in
duplicates either without or with the IDOlong peptide (bottom). (C), T-cell responses against IDOlong as measured by IL-17 ELISPOT: Example of an
ELISPOT response against IDOlong in PBMC from a breast cancer patient (Top). The average number of IDOlong-specific spots (after subtraction of
spots without added peptide) was calculated per 5610
5 PBMC for each patient. PBMC from nine healthy individuals (HD), twenty one melanoma
patients (MM), sixteen renal cell carcinoma patients (RCC) as well as nine breast cancer patients (BC) were analyzed. PBMC were stimulated once with
peptide before being plated at 5610
5 cells per well in duplicates either without or with the IDOlong peptide (bottom). (D), Percentage of donors
secreting none (white), one (black), two (dark grey) or all three (light grey) cytokines (IFN-c,TNF-a,IL-17) in response to IDOlong.
doi:10.1371/journal.pone.0034568.g001
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ognized by CD4
+ T cells both in cancer patients as well as healthy
individuals.
We show that IDO-specific CD4
+ T cells released IFN-c as well
as TNF-a. Hence, the data described here could suggest that such
CD4
+ T cells may play a supporting function by releasing Th1
cytokines in response to a peptide from an immune suppressive
molecule like IDO. Although, we were able to detect both IFN-c
and TNF-a response towards IDOlong in healthy donors, the
responses were more frequent in cancer patients. It is at this time
impossible to determent if the differences in the observed T-cell
responses between malignant melanoma and renal cell carcinoma
patients may reflect tumor associated effects or individual
heterogeneity. In this respect, we describe that IDOlong reacting
T-cells in addition react towards DC pulsed with IDO
+ tumor
lysates confirming the relevance of these T cells. We could in
contrast not detect any release of the Th2 cytokine IL-4 in
response to the IDO-derived peptide. IDO may be critical for the
strength and duration of a given immune response due to its
inflammation-induced counter-regulatory function. Hence, we
speculate that CD4
+ IDO-specific T cells releasing pro-inflamma-
tory cytokines may play an important role in the early phases of an
immune response as a counter-response to the induced regulatory
response facilitated by IDO
+ cells thereby delaying local immune
suppression. To this end, the activation of an IDO-specific CD4
+
Th1-response could prevail over the immune suppressive actions
of the IDO-protein, which are otherwise a result of the early
expression of IDO in maturing DC or macrophages.
It might be expected that IDO-specific T-cells themselves might
be vulnerable for IDO-mediated immune suppression or apopto-
sis. In this regard, the activation or inhibition of IDO-specific T-
cells may depend on a delicate balance; IDO-specific T-cells may
become functional when IDO are present in relative small amount
but they are inhibited like other T-cells when high amount of IDO
and/or other immune suppressive factors (e.g. TGF-b) are present.
In should,however, be mentioned that synovial auto reactive T
cells have been described in Rheumatoid Arthritis which were
resistant to IDO-mediated inhibition [26] due to enhanced storage
of intracellular tryptophan in such T-cells. It can be speculated
that IDO-specific T-cells are sustained in vivo in a similar manner.
We show that the CD4
+ T cell responses against the IDOlong
peptide indeed were HLA class II-restricted and, interestingly, in
Figure 2. HLA class II-restricted IDOlong responses as measured by IFN-cELISPOT. PBMC from one renal cell carcinoma patient (A) and five
melanoma patients (B,C,D,E,F) were stimulated once with peptide before being plated at either 2610
5 or 5610
5 cells per well in duplicates either
without or with the IDOlong peptide or without and with a monoclonal anti-HLA class II antibody. The average number of IFN-c releasing cells was
calculated either per 2610
5 PBMC or 5610
5 PBMC for each patient.
doi:10.1371/journal.pone.0034568.g002
Figure 3. CD4
+ T cell responses against IDO. (A), CD4
+ T cell responses against IDOlong as examined by IFN-c ELISPOT. PBMC from two
malignant melanoma patients (left, middle) and one renal cell carcinoma patient (right) were stimulated once with IDOlong peptide before CD4
+ T
cells were isolated. The CD4
+ cells were plated at 2610
5 cells per well in duplicates with 10
4 DC either without or with the IDOlong peptide. As a
control 10
4 DC were plated alone without T cells. The numbers of IFN-c releasing cells were counted for each patient. (B), ex vivo ELISPOT analysis of
CD4 T-cells isolated from three melanoma patients. CD4
+ cells were isolated from PBMC from three different donors and directly plated at 2610
5 cells
per well in duplicates with 10
4 DC either without or with the IDOlong peptide. HLA-class II antibody were added to two additional wells with CD4
cells, dendritic cells and IDOlong peptide. The numbers of IFN-c releasing cells were counted for each patient.
doi:10.1371/journal.pone.0034568.g003
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+ T cell responses T were
detectable in direct ex vivo assays. In this regard, it should be noted
that with a few exceptions it has not been possible to detect
conventional tumor antigen specific T cells in PBMC from cancer
patients directly ex vivo, i.e. without any in vitro steps to expand or
enrich these cells [27]. Thus, at least in some donors CD4 positive,
IDO-specific T cells were present in relative high frequencies.
Although, it has been described that T-cell epitopes often cluster
together at specific immunogenic regions it should be stressed that
we have only examined a small region of IDO and, consequently,
other IDO-derived CD4 epitopes most likely exist. Hence, the
frequency of donors with detectable levels of IDO specific T-cells
are most likely higher. The IDOlong peptide contains the HLA-
A2-restricted IDO-derived epitope named IDO5 (IDO199-207).
We could detect a correlation between patients harbouring
IDOlong responses and patients having the HLA class I tissue
type HLA-A2. We in addition detected an association between
IDOlong and IDO5 responses, which taken together suggest that
class I and class II restricted IDO responses co-develop.
We further described frequent IDO-specific CD4
+ T-cell
responses when examining for IL-17 release upon stimulation
with IDOlong peptide. IL-17 has been of great interest recently
owing to the discovery that the production of IL-17 characterizes
a subset of CD4
+ T-helper cells (Th17 cells). It is well described
that Th17 cells contribute to autoimmunity [28]. However, one of
the main roles of Th17 cells is to promote host defense against
infectious agents, and Th17 cells are thought to be particularly
important in maintaining barrier immunity at mucosal surfaces
such as in the lungs, gut and skin [29]. Interestingly, IDO is
expressed at high levels in the gastrointestinal tract, although its
precise role in intestinal immunity is not well understood [30].
The data presented here could suggest that the IDO-specific T
cells could be a part of the Th17 cells, which are highly prevalent
at the mucosal tissues of healthy individuals [29]. In cancer, Th17
cells might have a protective role in tumor immunopathology by
promoting antitumor immunity. Tumor-infiltrating Th17 cells
express other cytokines in addition to IL-17, which might be
functionally relevant [31,32]. There was no apparent difference in
the number of IL-17 releasing IDOlong reactive T-cells between
healthy donors and cancer patients. A large fraction of Th17 cells
produce high levels of effector cytokines such as IL-2, IFN-c as
well as TNF [33]. The data presented here suggest that IDO-
specific Th17 cells exhibit a similar effector T cell cytokine profile.
IDO is known to be induced by both type I and II interferon’s
[34,35]. Interestingly, it seemed that a higher number of IDO
responses were detected among melanoma patients that had
Figure 4. Intracellular cytokine staining. (A), TNF-a (top) and IFN-c (below) intracellular cytokine stainings. PBMC from two melanoma patients
were analyzed with and without IDOlong-stimulation. (B), PBMC from a melanoma patient were stimulated 2 times with autologous DC that had
been matured with IDOlong peptide in the presence of IL-2 before being analysed by intracellular TNF-a and IFN-c stainings. PBMC were stimulated
with autologous DC matured with either an irrelevant 20 amino acid long nonsense peptide, IDOlong peptide, lysate from the IDO
+ colon cancer cell
line SW480 or lysate from the IFN-c pre-treated melanoma cell line MM404.111. FACS plots were gated on live CD4
+ T-cells.
doi:10.1371/journal.pone.0034568.g004
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Furthermore, the IDO-responding patients seem to have an
extended period of stable disease after IL-2/IFNa therapy and
an overall prolonged survival although this was not statistical
significant. Finally, we were able to directly link the up regulation
of IDO with IDO-specific T cells by showing that the addition of
the IDO-inducing CpG ODN generated measurable numbers of
IDO-specific CD4 T cells among PBMC in vitro.
Figure 5. Correlation of CD4 responses against IDO with CD8 T-cell responses. (A), the correlation of IFN-c IDOlong responses with the
class I tissue type HLA-A2. A Mann-Whitney test demonstrated that for there was a significant difference between IFN-c responders and non-
responders (P=0.0003). (B), the correlation of TNF-a IDOlong responses with the class I tissue type HLA-A2. A Mann-Whitney test demonstrated that
there was not significant difference between TNF-a responders and non-responders (P=0.2). (C), correlation between IFN-c IDOlong responses and
IFN-cresponses against the HLA-A2-restricted, IDO-derived epitope IDO5 (IDO199-207). PBMC from IDO responders and non-responders were
stimulated with IDO5 once in vitro before being plated at 5610
5 cells per well in duplicates either without or with the IDO5 peptide. A Mann-Whitney
test demonstrated that for there was not significant difference between responders and non-responders (P=0.2). (D), correlation between IFN-c
IDOlong responses and IFN-c responses against HLA class I-restricted epitopes from CMV. PBMC from IDO responders and non-responders were
directly plated at 5610
5 cells per well in duplicates either without or with one of the most immunogenic HLA class I-restricted CMV-epitopes, i.e. the
HLA-A2-restricted epitope CMV pp65495–503 (NLVPMVATV), the HLA-A11-restricted epitope CMV pp6516–24 (GPISGHVLK), the HLA-A1- and HLA-A24-
restricted epitope CMV pp65341–350 (QYDPVAALFF) or the HLA-A1-restricted epitope CMV pp65363–373 (YSEHPTFTSQY) depending on the HLA-type of
the individual donor. A Mann-Whitney test illustrated that there was significant difference in T cell reactivity towards CMV epitopes between IDOlong
responders and non-responders (P=0.04).
doi:10.1371/journal.pone.0034568.g005
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systemic anti-cancer treatments for the anti-IDO responders and non-responders. Blood samples from melanoma patients were drawn at a minimum
of four weeks after termination of any kind of anti-cancer therapy. (B), Previous received treatment cycles of IL2/IFN for anti-IDO responders versus
non-responders of the malignant melanoma patients. The maximum number of cycles of this therapy is 6 due to severe toxicity. (C), Stable disease
period (RECIST v.1.0) after treatment with IL2/IFN-a for anti-IDO responders and non-responders. (D), Kaplan-Meier survival curve after diagnosis of
metastatic disease for anti-IDO responders and non-responders.
doi:10.1371/journal.pone.0034568.g006
Table 1. Patient characteristics.
Patients No=20 Responding patients No=12 Non-Responding Patients No=8
Age 62 years (49–78) 56 years (38–73)
Gender F=3 M=9 F=1 M=7
Stage of disease (IV) M1a=0 M1b=4 M1c=8 M1a=0 M1b=2 M1c=6
Performance status at leukopheresis PS 0=8 PS 1=4 PS 0=5 PS 1=3
Number of dendritic cell vaccines Vaccines=7.9 (5–13) Vaccines=8.3 (6–10)
Former treatment with IL2/IFN Yes=10 Yes=7
Number of IL2/IFN Cycles=3.2 Cycles=2.
Response to IL2/IFN SD=3.8 months (0–14) SD=2.1 months (0–5)
Number of systemic treatments Regimes=2.5 (1–4) Regimes=2.9 (1–4)
Time from disseminated MM until death 19.8 months (9–44) 17.3 months (10–28)
doi:10.1371/journal.pone.0034568.t001
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+ T-cell response to CMV typically constitutes a
sizeable percentage of the CD8
+ T-cell repertoire in CMV-
seropositive individuals [36]. CMV has been shown to induce
IDO expression in monocytes, which might present an advantage
to CMV-infected monocytes to escape T-cell responses [37]. Here
we show that the presence of IDOlong responses correspond to the
presence of CMV-responses, which could suggest that the IDO
specific T cells function as supporter T cells for the constitutive
anti-CMV CD8
+ T-cell response.
Interestingly, in some donors we detected background IL-10
release in in vitro pre-stimulated ELISPOT assays. This enabled us
to perceive that stimulation with the IDO-derived peptide in two
healthy donors triggered an overall suppression of IL-10. In this
regard, we have previously observed a decrease in IL-10 when
IDO-specific CD8
+ T cells were present [16]. However, we could
in additional donors detect IL-10 release in response to IDOlong
peptide. IL-10 is mainly expressed by Tregs that have been
defined as a specialized subpopulation of T cells that act to
suppress activation of the immune system and thereby maintain
immune system homeostasis and tolerance to self-antigens.
Consequently, it can be speculated that IDO-specific Tregs may
enhance the IDO-mediated immune suppression protecting cells
from an immune attack. Hence, the role of IDO-specific CD4
+ T
cells in immune-regulatory networks may be a complex balance
between activation and inhibition depending on the microenvi-
ronment. In this respect, it was recently described that IDO play
biologically important roles in the host response to diverse
intracellular infections but in addition that the nature of this role
– antimicrobial or immune regulatory - might depend on the
pathogen. Hence, IDO inhibition might not always benefit the
host. In this regard, IDO inhibition during murine toxoplasmosis
led to increased mortality with increased parasite burdens [38].
This should naturally be taken into account when exploring the
possible use of IDO-specific T-cells in the clinic.
In conclusion, we describe the presence of naturally occurring
IDO-specific CD4
+ T-helper cells in cancer patients and in
healthy donors. We suggest that the activation of such CD4
+ cells
could help overcoming the immune suppressive actions of the
IDO-protein, which are otherwise a result of the early expression
of IDO in maturing antigen-presenting cells. However, since IDO-
Figure 7. IDOlong contains various T cell epitopes. (A) PMBC from seven patients (1 breast cancer patient and 6 melanoma patients) were
analysed for responses against IDO194 (DTLLKALLEIASCLE (IDO194-208)) (grey bars), IDO200 (LLEIASCLEKALQVF (IDO200-214)) (white bars) and
compared to IDOlong (black bars) by IFN-c ELISPOT assay. The average number of peptide-specific spots (after subtraction of spots without added
peptide) was calculated per 5610
5 PBMC for each patient. PBMC were stimulated once with peptide before being plated at 5610
5 cells per well in
duplicates either without or with the peptide. (B), CpG stimulate IDO-specific T cells. PBMC from a melanoma patient and a renal carcinoma patient
were treated with either IL-2 or the TLR9 ligand CpG ODN in the presence of IL-2 for 14 days and, subsequently, examined for IDO-specific T cells by
TNF-a ELISPOT. Hence, PBMC were plated at 5610
5 cells per well in duplicates either without or with the IDOlong peptide before and after cell
culture. The average number of TNF-a releasing cells was calculated per 2610
5 PBMC for each patient.
doi:10.1371/journal.pone.0034568.g007
Figure 8. T-cell responses against IDOlong as measured by IL-
10 ELISPOT. PBMC from six healthy individuals (HD1-6), sixteen
melanoma patients (MM1-16) and nine renal cell carcinoma patients
(RCC1-9) were analyzed. PBMC were stimulated once with peptide
before being plated at 5610
5 cells per well in duplicates either without
(black bars) or with the IDOlong peptide (grey bars).
doi:10.1371/journal.pone.0034568.g008
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+ T cells in addition may secrete regulatory cytokines
the balance between activation and inhibition may vary depending
on the phenotype that yet again may depend on the microenvi-
ronment.
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